The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase III randomized double-blind study of prophylactic topical dapsone 5% versus moisturizer for cetuximab-induced papulopustular (acneiform) rash.
 
Mario E. Lacouture
Honoraria - Advancell; Aveo; Bayer; BIOPHARM; Boehringer Ingelheim; Brickell Biotech; Bristol-Myers Squibb; Clinical Assistance Programs LLC; Clinical Care Options; EMD Serono; Envision Communications; Foamix; Galderma; Genentech/Roche; GlaxoSmithKline; Helsinn Healthcare; Helsinn Healthcare; Medscape; Merck; NeRRe Therapeutics; Novartis; Novocure; Oncology Specialty Group; Pfizer; Pierre Fabre; Threshold Pharmaceuticals
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Brickell Biotech; Bristol-Myers Squibb; EMD Serono; Foamix; Galderma; Genentech/Roche; GlaxoSmithKline; Helsinn Healthcare; Merck; Novartis; Novocure; Pfizer; Pierre Fabre; Threshold Pharmaceuticals
Research Funding - Berg Pharma (Inst)
 
Viswanath Reddy Belum
No Relationships to Disclose
 
Danielle Kehn
No Relationships to Disclose
 
Andrea Cercek
No Relationships to Disclose
 
Nancy E. Kemeny
Research Funding - Amgen (Inst)